Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284485 · ClinicalTrials.gov registry record · Phase 2
Immunoprevention for High-risk Lung Lesions
A Phase 2 study of High-risk Lung Nodules, sponsored by Robert Samstein.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT07284485: Recruiting Phase 2 study of High-risk Lung Nodules, sponsored by Robert Samstein.
NCT07284485 is a Phase 2 study of High-risk Lung Nodules that is actively recruiting participants, run by Robert Samstein. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07284485, a Phase 2 study of High-risk Lung Nodules, is actively recruiting participants, sponsored by Robert Samstein.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
Primary Outcome
Response rate is defined as the proportion of patients who achieve this regression on imaging obtained at 3 months. Regression will be defined as ≥20% reduction in the largest diameter of at least one lung nodule at 3 months after initiation of biologic therapy.
Conditions Studied
Interventions
- BIOLOGICAL Nadunolimab
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2029-12-17 |
| Phase | Phase 2 |
What NCT07284485 shows while recruiting
NCT07284485 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 1 condition, with High-risk Lung Nodules appearing as the primary indexed condition, and to 1 intervention - of which Nadunolimab is the first listed.
NCT07284485 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07284485 about?
NCT07284485 is a clinical study titled "Immunoprevention for High-risk Lung Lesions". The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
What is the current status of trial NCT07284485?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2026-04-01. Estimated completion is 2029-12-17.
What conditions does trial NCT07284485 study?
This clinical trial studies the following conditions: High-risk Lung Nodules.
What interventions are being tested in trial NCT07284485?
The interventions under investigation include: Nadunolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT07284485?
This trial is sponsored by Robert Samstein, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284485 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07284485's enrollment target sits among peer trials
59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI